Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sean Hailey

Nurse Practitioner Lewiston, NY Nurse Practitioner

NPI 1245405158 CMS profile 10429661

5290 Military Road Suite 10 A & B, Lewiston, NY 14092

Open in the dashboard

General payments

$2,606

137 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sean Hailey of Lewiston, NY is reported in the CMS Open Payments database as having received $2,606 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $882 46
2024 General $561 33
2023 General $706 32
2022 General $310 21
2021 General $147 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sean Hailey
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sean Hailey were reported at $882. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sean Hailey Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $147 $135 $40–$426 $132
2022 $310 $152 $48–$470 $149
2023 $706 $166 $54–$529 $160
2024 $561 $173 $55–$556 $164
2025 $882 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $318 20 payments
  2. AbbVie, Inc. $241 12 payments
  3. Pfizer Inc. $225 13 payments
  4. Novo Nordisk Inc $193 11 payments
  5. GlaxoSmithKline, LLC. $178 11 payments
  6. Amgen Inc. $160 9 payments
  7. Abbott Laboratories $136 11 payments
  8. Idorsia Pharmaceuticals US Inc $125 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $90 1 payment
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $86 4 payments
  11. Other $855 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,606 137 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $195 13 payments
  2. TRELEGY ELLIPTA $148 9 payments
  3. UBRELVY $137 7 payments
  4. ZEPBOUND $136 8 payments
  5. Ozempic $136 8 payments
  6. QUVIVIQ $125 1 payment
  7. JARDIANCE $122 7 payments
  8. RYBELSUS $122 7 payments
  9. FreeStyle Libre 2 $121 10 payments
  10. Otezla $111 6 payments
  11. Other $1,972 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

4,462

Median for Nurse Practitioner: 389

Drug cost

$362,266

Median for Nurse Practitioner: $21,885

Branded share of claims

19.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 65 $56,235
Trulicity Dulaglutide Brand 28 $51,235
Jardiance Empagliflozin Brand 44 $47,005
Repatha Sureclick Evolocumab Brand 51 $28,903
Xarelto Rivaroxaban Brand 21 $25,176
Mounjaro Tirzepatide Brand 18 $22,181
Synjardy Xr Empagliflozin/Metformin Hcl Brand 11 $15,680
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $14,872
Ozempic Semaglutide Brand 15 $14,144
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 74 $10,383

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$13,624

Of which drugs: $2,287

Medicare patients

136

Average age 74

Services billed

382

62 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Ischemic heart disease 35%
Diabetes 33%
Depression 32%
Chronic kidney disease 31%
Cancer 26%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 17 17 $1,391

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $101
$101 18 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $53
$53 — —
ZEPBOUND
  • Lilly USA, LLC $51
$51 — —
Veozah
  • Astellas Pharma US Inc $40
$40 — —
YUPELRI
  • Mylan Specialty L.P. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record